BioLegacy delivers the comprehensive safety profile required to confidently advance your program to the clinic. From discovery toxicology to GLP-compliant, IND-enabling studies, we thoroughly interrogate your therapeutic’s effect on all vital organ systems. Our expertise provides the definitive, submission-ready data needed to ensure your program is built on a foundation of regulatory success. From discovery toxicology to GLP-compliant, IND-ready studies, BioLegacy provides a full suite of toxicology and safety pharmacology services. We examine your therapeutic’s effect on all vital systems, including central nervous, cardiovascular, and respiratory functions. Our expertise in acute, subchronic, and chronic toxicity studies ensures a comprehensive safety profile to confidently advance your program to the clinic.
Toxicology
Pharmacology
BioLegacy elucidates the pharmacokinetics and pharmacodynamics of your therapeutic within highly translatable, disease-relevant in vivo systems. Our extensive expertise in pharmacology is coupled with a comprehensive suite of bioanalytical capabilities, ensuring the generation of definitive, high-fidelity data. Take advantage of our GLP-compliant data packages to facilitate accelerated IND submissions.
- PK/PD
- ADME
- GLP / non-GLP
- Many species, including NHPs
- 100s of in vivo disease models
Animal Model Development
BioLegacy specializes in the de novo development of bespoke in vivo models, leveraging a comprehensive platform that includes transgenics, targeted mutations, xenografts, and chemical or surgical induction. This allows for the creation of precisely engineered biological systems to interrogate your therapeutic’s unique mechanism of action and deliver definitive, clinically-relevant data.
Ensure maximum translational fidelity and overcome the limitations of existing models with BioLegacy.
- Complete range of research-relevant species, from mice to NHPs
- Expertise in genetic, humanized, induced, and other models
In Vitro Screening
Optimize leads with confidence! BioLegacy’s range of screening platforms employ physiologically-relevant cellular assays, quantitative biophysical assays, and high throughput biochemical assays to provide rich mechanistic, affinity, and predictive ADMET data. De-risk your pipeline with rich data on target engagement, biomarkers, and mechanism-of-action.
- Extensive biolanalytical capabilities
- High-throughput biomarker analysis
- Dozens of cell-based assays
- Antibody production & characterization
- Comprehensive in vitro toxicological analyses
Custom Assay Development
BioLegacy develops bespoke in vitro assays for the pharmacological deconvolution of your lead candidates. Our platforms provide definitive data on mechanism of action, potency, and cytotoxicity, moving beyond standard panels to answer your program’s most critical questions. By integrating our deep expertise in cellular phenotyping and high-throughput bioanalysis, we construct, optimize, and validate novel functional assays that deliver a precise, decision-enabling data package.
- Choose from hundreds of cell lines
- Custom bioanalytical method development
- High-throughput formats available
Histology
BioLegacy provides definitive, submission-ready data histological and pathological data. Our full suite of techniques — from routine H&E to advanced IHC, ISH, and TUNEL assays — elucidate your compound’s efficacy, target engagement, and safety profile at the cellular level. BioLegacy delivers objective, reproducible data packages to empower go/no-go decisions and IND submissions.
- In-house histology suite for rapid, professional turnaround
- Advanced microscopy technologies & methods
- Long-term sample & tissue storage
- GLP or non-GLP
- Certified board pathologist on staff
